Neurocrine Biosciences

Forecast & Rating27 analysts currently cover Neurocrine Biosciences, with about 85.2% giving a positive rating — meaning they expect the stock to rise. The average price target is $210.79, about 34.0% upside from the current price of $157.30. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 78.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Neurocrine Biosciences closely still see room for the stock to rise. Data as of Sep 11, 2026; for reference only and not investment advice.